NCT05702424View on ClinicalTrials.gov

Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

January 10, 2023

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2024

Conditions
Solid Tumor
Interventions
DRUG

IGM-7354

IGM-7354 is a PD-L1-targeted cytokine that is designed to regulate T and natural killer cell activation, proliferation and promote their anti-tumor effects

Trial Locations (5)

28078

Carolina Biooncology Institute, Huntersville

34232

Florida Cancer Specialists & Research Institute, Sarasota

73019

Oklahoma University, Norman

78229

START South Texas Accelerated Research Therapeutics, San Antonio

06520

Yale University, New Haven

Sponsors
All Listed Sponsors
lead

IGM Biosciences, Inc.

INDUSTRY

NCT05702424 - Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer | Biotech Hunter | Biotech Hunter